

# Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1     **New insights on the effects of formulation type and compositional mixtures over**  
2             **the antioxidant and cytotoxic activities of dietary supplements based-on**  
3                     **hepatoprotective plants**

4  
5     Carla Pereira<sup>a</sup>, João C.M. Barreira<sup>a</sup>, Ricardo C. Calhela<sup>a,b</sup>, Maria João R.P. Queiroz<sup>b</sup>,  
6                     Lillian Barros<sup>a</sup>, Isabel C.F.R. Ferreira<sup>a,\*</sup>

7  
8     <sup>a</sup>Centro de Investigação de Montanha (CIMO), ESA, Instituto Politécnico de Bragança,  
9     Campus de Santa Apolónia, apartado 1172, 5301-855 Bragança, Portugal

10    <sup>b</sup>Centro de Química, Universidade do Minho, Campus de Gualtar 4710-057 Braga,  
11    Portugal

12  
13    \* Author to whom correspondence should be addressed (e-mail: iferreira@ipb.pt telephone +351-273-  
14    303219; fax +351-273-325405).

15

16

17 **Abstract**

18 Artichoke (A), borututu (B) and milk thistle (M) are included in several supplements to  
19 provide beneficial effects. Different formulations (infusions, pills and syrups), as also  
20 different proportions of A, B and M (1:1:1, 2:1:1, 1:2:1, 1:1:2) within each formulation  
21 were assayed to optimize the desired benefits. The antioxidant activity, anti-  
22 hepatocellular carcinoma activity, hepatotoxicity and bioactive compounds contents  
23 were evaluated. Syrups tended to be the formulation with highest antioxidant activity  
24 and total phenolics and flavonoids content; otherwise, pills were the worst formulation.  
25 In what concerns A:B:M ratios, the results did not reveal so pronounced differences.  
26 None of the assayed mixtures resulted to be toxic (up to the maximum assayed dose) for  
27 liver primary cells (PLP2), but some samples, especially infusions, showed toxicity for  
28 the hepatocellular carcinoma cell line (HepG2). With no exception, the mixtures for all  
29 formulations gave synergistic effects in antioxidant activity, when compared to the  
30 activity of single plants.

31

32 *Keywords:* Dietary supplements; Formulation; Compositional mixture; Bioactivity;  
33 Citotoxicity; Synergism

34

35

## 36 Introduction

37 Artichoke (*Cynara scolymus* L.), borututu (*Cochlospermum angolensis* Welw.) and  
38 milk thistle (*Silybum marianum* (L.) Gaertn) are medicinal plants with numerous  
39 pharmacological effects, such as antioxidant and hepatoprotective activities, as  
40 described in different studies;<sup>1-3</sup> borututu is also recognized as an antimalarial herb,<sup>4</sup>  
41 while milk thistle prevent spleen and gallbladder disorders,<sup>5</sup> and artichoke leaves are  
42 used for the treatment of dyspepsia and diabetes.<sup>6</sup>

43 Phytochemicals are very prone to variations depending on the plant material (that  
44 changes within phenological cycle), harvest, drying and storage conditions.<sup>7</sup> The  
45 genetic, cultural and environmental factors that explain this variability make their use  
46 rather challenging and frequently problematic because the active principles are diverse  
47 and may be unknown.<sup>7,8</sup> In some cases, these effects might even be harmful; for  
48 instance, the leaf extracts of artichoke caused chromosomal instability and cytotoxicity  
49 in hamster ovary cells,<sup>9</sup> while milk thistle extracts, at 15 µg/mL, showed toxicity against  
50 the activity of hepatic P450 cytochrome.<sup>10</sup>

51 The consumption of supplements to provide the beneficial effects of certain plants has  
52 raised several controversial questions, such as those pointed out by Halliwell, who  
53 stated that “we cannot just pull out one or two individual molecules and expect pills  
54 containing high doses of them to protect us”,<sup>11</sup> suggesting the whole herbal medicine as  
55 one active ingredient, *i.e.*, a set of multi-component parts self-organized into an  
56 indivisible whole.<sup>12</sup> Nonetheless, there is an increasing number of formulations based  
57 on these plants due to their therapeutic applications, namely infusions, pills, capsules,  
58 ampoules, syrups, among others.

59 The bioactivity of the most consumed forms (infusions, pills, and syrups) of borututu,  
60 milk thistle, and artichoke was assessed by our research group and these formulations

61 revealed not only antioxidant and hepatoprotective effects, but also synergism between  
62 the three plants in syrups.<sup>13,14</sup> Thus, given the importance of the studied plants in the  
63 treatment of liver diseases and the availability of so many formulations, it seems very  
64 pertinent to find the better way to achieve the desired benefits from these herbs  
65 depending on the kind of formulation, the plant present on it, or even the percentage of  
66 each plant in formulations containing the three mentioned plants. To deepen that  
67 question, in the present work we investigated the antioxidant and anti-hepatocellular  
68 carcinoma activities of twelve mixtures with four different proportions of artichoke,  
69 borututu and milk thistle, and different formulations of each plant (infusions, pills and  
70 syrups).

71

## 72 **Experimental**

### 73 **Samples and samples preparation**

74 *Cynara scolymus* L. (artichoke; A), *Cochlospermum angolensis* Welw. (borututu; B)  
75 and *Silybum marianum* (L.) Gaertn (milk thistle; M) were obtained from an herbalist  
76 shop in Bragança (Portugal), as dry material for infusions (leaves, plant and bark,  
77 respectively), pills (based-on plant and roots, in the case of B), and syrups (containing  
78 100% of A, 10% of B roots, and 2.3% of M). Each sample was used as recommended in  
79 the label: the infusions were prepared from the dry material and further lyophilized, the  
80 pills were powdered and the syrups were directly used.

81 Each formulation (infusion, pill and syrup) of A, B and M, respectively, was mixed in  
82 different proportions: 1:1:1; 2:1:1; 1:2:1; and 1:1:2 (*m/m/m*), and further dissolved in  
83 distilled water to a final concentration of 6 mg/mL. The twelve stock solutions (four  
84 mixtures of infusions, four mixtures of pills and four mixtures of syrups) were

85 successively diluted and submitted to an evaluation of antioxidant activity, anti-  
86 hepatocellular carcinoma activity and hepatotoxicity.

87

### 88 **Standards and reagents**

89 2,2-Diphenyl-1-picrylhydrazyl (DPPH) was obtained from Alfa Aesar (Ward Hill, MA,  
90 USA). Gallic acid, catechin, trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-  
91 carboxylic acid), ellipticine, phosphate buffered saline (PBS), acetic acid,  
92 sulforhodamine B (SRB), trichloroacetic acid (TCA) and Tris were purchased from  
93 Sigma (St. Louis, MO, USA). Foetal bovine serum (FBS), L-glutamine, Hank's  
94 balanced salt solution (HBSS), trypsin-EDTA (ethylenediaminetetraacetic acid),  
95 nonessential amino acids solution (2 mM), penicillin/streptomycin solution (100 U/mL  
96 and 100 mg/mL, respectively) and DMEM (Dulbecco's Modified Eagle Medium) were  
97 from Hyclone (Logan, UT, USA). Water was treated in a Milli-Q water purification  
98 system (TGI Pure Water Systems, Greenville, SC, USA).

99

### 100 **Antioxidant activity**

101 DPPH radical-scavenging activity was evaluated by using an ELX800 microplate reader  
102 (Bio-Tek Instruments, Inc; Winooski, VT, USA), and calculated as a percentage of  
103 DPPH discolouration using the formula:  $[(A_{\text{DPPH}} - A_{\text{S}}) / A_{\text{DPPH}}] \times 100$ , where  $A_{\text{S}}$  is the  
104 absorbance of the solution containing the sample at 515 nm, and  $A_{\text{DPPH}}$  is the  
105 absorbance of the DPPH solution. Reducing power was evaluated by the capacity to  
106 convert  $\text{Fe}^{3+}$  into  $\text{Fe}^{2+}$ , measuring the absorbance at 690 nm in the microplate reader  
107 mentioned above. Inhibition of  $\beta$ -carotene bleaching was evaluated through the  $\beta$ -  
108 carotene/linoleate assay; the neutralization of linoleate free radicals avoids  $\beta$ -carotene  
109 bleaching, which is measured by the formula:  $\beta$ -carotene absorbance after 2h of

110 assay/initial absorbance)  $\times 100$ . Lipid peroxidation inhibition in porcine (*Sus scrofa*)  
111 brain homogenates was evaluated by the decreasing in thiobarbituric acid reactive  
112 substances (TBARS); the colour intensity of the malondialdehyde-thiobarbituric acid  
113 (MDA-TBA) was measured by its absorbance at 532 nm; the inhibition ratio (%) was  
114 calculated using the following formula:  $[(A - B)/A] \times 100\%$ , where A and B were the  
115 absorbance of the control and the sample solution, respectively.<sup>15</sup> The results were  
116 expressed in EC<sub>50</sub> values (sample concentration providing 50% of antioxidant activity  
117 or 0.5 of absorbance in the reducing power assay). Trolox was used as positive control.

118

#### 119 **Bioactive compounds content**

120 Total phenolics were estimated by Folin-Ciocalteu colorimetric assay according to  
121 procedures previously described<sup>16</sup> and the results were expressed as mg of gallic acid  
122 equivalents (GAE) per g of extract.

123 Total flavonoids were determined by a colorimetric assay using aluminum trichloride,  
124 following procedures previously reported;<sup>16</sup> the results were expressed as mg of (+)-  
125 catechin equivalents (CE) per g of extract.

126

#### 127 **Anti-hepatocellular carcinoma activity and hepatotoxicity**

128 The anti-hepatocellular carcinoma activity was evaluated using HepG2, which is the  
129 most widely used tumor cell line and generally regarded as a good hepatocellular  
130 carcinoma model. HepG2 cells were routinely maintained as adherent cell cultures in  
131 DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100  
132 mg/mL streptomycin, at 37 °C, in a humidified air incubator containing 5% CO<sub>2</sub>. The  
133 cell line was plated at  $1.0 \times 10^4$  cells/well in 96-well plates. Sulforhodamine B assay  
134 was performed according to a procedure previously described by the authors.<sup>17</sup>

135 For hepatotoxicity evaluation, a cell culture was prepared from a porcine liver obtained  
136 from a local slaughter house, according to a procedure established by the authors;<sup>17</sup> it  
137 was designed as PLP2. Cultivation of the cells was continued with direct monitoring  
138 every two to three days using a phase contrast microscope. Before confluence was  
139 reached, cells were subcultured and plated in 96-well plates at a density of  $1.0 \times 10^4$   
140 cells/well, and commercial in DMEM medium with 10% FBS, 100 U/mL penicillin and  
141 100  $\mu\text{g/mL}$  streptomycin. The results were expressed in  $\text{GI}_{50}$  values (sample  
142 concentration that inhibited 50% of the net cell growth). Ellipticine was used as positive  
143 control.

144

#### 145 **Classification of additive, synergistic or antagonistic effects**

146 Theoretical values for antioxidant and anti-hepatocellular carcinoma activities of the  
147 mixtures were calculated as weighted mean experimental  $\text{EC}_{50}$  or  $\text{GI}_{50}$  values of the  
148 individual samples<sup>14</sup> and considering additive contributions of individual species in each  
149 percentage; for instance, mixture 2:1:1:  $\text{EC}_{50} = \text{EC}_{50A} \times 0.5 + \text{EC}_{50B} \times 0.25 +$   
150  $\text{EC}_{50M} \times 0.25$ .

151 The classification in additive (AD), synergistic (SN) or antagonistic (negative  
152 synergistic; AN) effects was performed as follow: AD: theoretical and experimental  
153 values reveal differences lower than 5%; SN: experimental values are more than 5%  
154 lower than theoretical values; AN: experimental values are more than 5% higher than  
155 theoretical values. For each case, the percentage was calculated as follows:  
156  $[(\text{experimental value} - \text{theoretical value}) / \text{experimental value}] \times 100$ .

157

#### 158 **Statistical analysis**



159 All statistical tests were performed at a 5% significance level, using SPSS (v.20)  
160 software. For each formulation (F) and A:B:M ratio (R), three samples were analyzed,  
161 with all the assays being also carried out in triplicate. The results are expressed as mean  
162 value±standard deviation (SD).

163 An analysis of variance (ANOVA) with type III sums of squares was performed using  
164 the GLM (General Linear Model) procedure of the SPSS software. The dependent  
165 variables were analyzed using 2-way ANOVA, with the factors F and R. In this case,  
166 when a statistically significant interaction (F×R) is detected, the two factors should be  
167 evaluated simultaneously by the estimated marginal means plots for all levels of each  
168 single factor. Alternatively, if no statistical significant interaction is verified, means  
169 might be compared using, for instance, Tukey's honestly significant difference (HSD)  
170 multiple comparison test.

171 Furthermore, a linear discriminant analysis (LDA) was used to compare the effect of F  
172 and R on antioxidant activity and extracted bioactive compounds. A stepwise technique,  
173 using the Wilks'  $\lambda$  method with the usual probabilities of  $F$  (3.84 to enter and 2.71 to  
174 remove), was applied for variable selection. This procedure uses a combination of  
175 forward selection and backward elimination processes, where the inclusion of a new  
176 variable is preceded by ensuring that all variables selected previously remain  
177 significant.<sup>18,19</sup> With this approach, it is possible to identify the significant variables  
178 obtained for each sample. To verify the significance of canonical discriminant  
179 functions, the Wilks'  $\lambda$  test was applied. A leaving-one-out cross-validation procedure  
180 was carried out to assess the model performance.

181

## 182 **Results and Discussion**

183 **Antioxidant properties and cytotoxicity for hepatocellular tumor cell line and liver**  
184 **primary cells**

185 There has been an intensive scientific effort to validate the effectiveness of herbal  
186 formulations, since the preparation of dietary supplements/nutraceuticals and some  
187 pharmaceutical products are based on the extraction of bioactive compounds from  
188 natural products.<sup>20</sup> This scientific validation is often supported by evaluating the  
189 antioxidant activity of plant derived products, as a preliminary approach. Herein, four  
190 different assays were used: DPPH scavenging activity, reducing power (assessed by  
191 Ferricyanide/Prussian blue assay),  $\beta$ -carotene bleaching inhibition and TBARS  
192 formation inhibition. In addition, total phenolics and total flavonoids were also  
193 determined, bearing in mind that the antioxidant activity is often correlated with the  
194 contents in phenolic compounds.<sup>21</sup> Also, HepG2 human cell line was used to assess  
195 anti-hepatocellular carcinoma activity, while a primary culture of porcine liver cells was  
196 established to evaluate hepatotoxicity. In fact, since some potential effects of  
197 compounds naturally present in plants are difficult to anticipate, the assessment of the  
198 safety of a plant extract used as a food or a medicine by the population is completely  
199 mandatory.<sup>9</sup>

200 Three plant species, namely artichoke (A), borututu (B) and milk thistle (M), which are  
201 commonly present in nutraceutical formulations/dietary supplements, were selected due  
202 to their availability in different formulations. Besides aiming studying the influence of  
203 the formulation type in the bioactivity and phenolic compounds content, this study was  
204 designed also to evaluate supposed differences resulting from using different  
205 percentages of the plant species in each formulation.

206 The effects of formulation type (F) and A:B:M ratio (R) were evaluated by fixing one of  
207 the factors; *i.e.*, the results are presented as the mean of each F, comprising values for

208 all R in those conditions, as well as the mean of each R, containing the results for all the  
209 corresponding F. Accordingly, the standard deviation values should not be looked up as  
210 a simple measure of assays repeatability, since they reflect results from assays  
211 performed in different conditions.

212 As it can be seen in **Table 1**, each factor showed a significant effect *per se*, but the  
213 interaction among factors (F×R) was also a significant ( $p<0.001$ ) source of variation for  
214 all parameters, indicating a strong interaction between the formulation and the  
215 percentages of each plant in the prepared mixtures. Therefore, although the least squares  
216 means are presented, the results for multiple comparisons became meaningless.  
217 Nevertheless, from the analysis of the plots of the estimated margins means (**Figures 1**  
218 **and 2**), some particular tendencies can be observed. For instance, pill formulation gave  
219 lower antioxidant activity in all antioxidant assays (DPPH scavenging activity:  $EC_{50} =$   
220  $1.2 \text{ mg/mL}$ ; reducing power:  $EC_{50} = 0.4 \text{ mg/mL}$ ;  $\beta$ -carotene bleaching inhibition:  $EC_{50}$   
221  $= 2 \text{ mg/mL}$ ; TBARS formation inhibition:  $EC_{50} = 0.3 \text{ mg/mL}$ ) and also lower contents  
222 in total phenolics (69 mg GAE/g) and total flavonoids (5 mg CE/g) contents; syrups and  
223 infusions presented similar antioxidant activity levels, except for reducing power (lower  
224 on infusion), but total phenolics (469 mg GAE/g) and total flavonoids (78 mg CE/g)  
225 contents were higher in syrups. In what concerns A:B:M ratios, the results did not  
226 reveal so pronounced differences, except for the lower DPPH scavenging activity ( $EC_{50}$   
227  $= 1.0 \text{ mg/mL}$ ),  $\beta$ -carotene bleaching inhibition ( $EC_{50} = 2 \text{ mg/mL}$ ) and TBARS  
228 formation inhibition ( $EC_{50} = 0.2 \text{ mg/mL}$ ) in mixtures 2:1:1, 1:1:2 and 1:1:1,  
229 respectively.

230 Besides the pointed out differences, the assayed mixtures and formulations proved to  
231 have higher antioxidant activity than previously assayed formulations, namely syrups  
232 with a A:B:M ratio of 1:1:2.35, except in the case of  $\beta$ -carotene bleaching inhibition, to

233 which the results were similar.<sup>14</sup> A similar result was obtained for the anti-  
234 hepatocellular carcinoma activity, which demonstrated to be higher in the present report  
235 when compared to the results obtained from infusion, pills or syrups based on a single  
236 species or in mixtures different than those assayed herein. This antitumor activity was  
237 especially high in infusions (1:1:1,  $GI_{50} = 24 \mu\text{g/mL}$ ; 2:1:1,  $GI_{50} = 49 \mu\text{g/mL}$ ; 1:2:1,  
238  $GI_{50} = 63 \mu\text{g/mL}$ ; 1:1:2,  $GI_{50} = 67 \mu\text{g/mL}$ ). None of the samples showed hepatotoxicity  
239 ( $GI_{50} > 400 \mu\text{g/mL}$ , in all cases), which represents an important result considering the  
240 need of obtaining innocuous formulations.

241

#### 242 **Additive, synergistic or antagonistic effects**

243 When comparing with the antioxidant activity and bioactive compounds content of each  
244 plant *per se*, the results obtained for the present mixtures and formulations are close to  
245 those reported for borututu, which is, by far, the plant with most active derived products  
246 among the three assayed species.<sup>13</sup> As a consequence, the possibility of having a  
247 synergistic effect within the prepared mixtures was raised. This hypothesis was  
248 mathematically verified by calculating the simple mean (for 1:1:1 mixture), or the  
249 weighted mean (in all remaining mixtures). The results of these calculations are  
250 indicated as theoretical values (**Table 2**); regarding the anti-hepatocellular carcinoma  
251 activity, the  $GI_{50}$  values higher than  $400 \mu\text{g/mL}$  (the maximum assayed concentration)  
252 were included as being 400, since this is precisely the value that most hinder the  
253 possible synergistic effect; *i.e.*, if a given mixture shows synergistic effect when  
254 considering the  $GI_{50}$  value of a determined plant (or plants) as being  $400 \mu\text{g/mL}$  instead  
255 of the non-obtained (higher) experimental value, than the effect resulting from including  
256 the real experimental value, would certainly be synergistic. With no exception, the  
257 mixtures of all formulations gave synergistic effects in antioxidant activity. In fact, the

258 highest activity of mixtures when compared to the individual plants was previously  
259 observed in formulations containing fennel, lemon-verbena and spearmint.<sup>22</sup>  
260 Nevertheless, the mixtures 2:1:1 and 1:1:2, for pills and syrups, and also mixture 1:2:1,  
261 for syrups, did not result in a synergistic effect in what regards the anti-hepatocellular  
262 carcinoma activity on HepG2. The hepatotoxicity, as evaluated on PLP2 cells, was  
263 always lower in the mixtures, when compared to the activity of single plants,<sup>13,14</sup> which  
264 represents also a good result considering the previously stated objective of obtaining  
265 non-toxic mixed formulations.

266

### 267 **Linear discriminant analysis of antioxidant properties**

268 In order to have a complete perspective about the effect of F and R on the antioxidant  
269 activity and bioactive compounds amounts, two linear discriminant analysis were  
270 applied (the anti-hepatocellular carcinoma activity and hepatotoxicity results were not  
271 included, since there were some cases with  $GI_{50} > 400 \mu\text{g/mL}$  that could not be  
272 included). The significant independent variables (results for antioxidant activity assays  
273 and bioactive compound contents) were selected following the stepwise method of the  
274 LDA, according to the Wilks'  $\lambda$  test. Only variables with a statistically significant  
275 classification performance ( $p < 0.05$ ) were kept in the analysis.

276 In the case of F effect, 2 significant functions were defined (plotted in **Figure 3**), which  
277 included 100.0% of the observed variance (first, 58.2%; second, 41.8%). As it can be  
278 observed, the tested groups (infusion, pill and syrup) were completely individualized  
279 (shadowed ellipses). Function 1 was primarily correlated to TBARS formation  
280 inhibition, DPPH scavenging inhibition and  $\beta$ -carotene bleaching inhibition, which were  
281 much lower in pill formulation. Actually, this function separated mainly pills from the  
282 remaining formulations, as confirmed by the means of canonical variance (MCV:

283 infusion, -4.684; pill, 5.212; syrup, -0.529. Function 2, by its side, was more correlated  
284 to reducing power (lower in syrup), total phenolics and total flavonoids (in higher  
285 quantities in syrups). Accordingly, as it can be seen in the vertical axis, function 2  
286 clearly separated syrup formulation (MCV: infusion, -2.806; pill, -2.031; syrup, 4.837).  
287 All samples were correctly classified, either for original grouped cases, as well as for  
288 cross-validated grouped cases.

289 Regarding A:B:M ratio, the discriminant model selected 3 significant functions (**Figure**  
290 **4**), which included 100.0% of the observed variance (function 1: 65.3%, function 2:  
291 20.9%, function 3: 13.8%). In this case, the tested groups (1:1:1, 2:1:1, 1:2:1 and 1:1:2)  
292 were not completely individualized, indicating that the differences determined in the  
293 antioxidant activity assays and bioactive compounds contents were not enough to  
294 discriminate the tested groups. The classification performance allowed 65% of correctly  
295 classified samples (sensitivity) and 64% of overall specificity within the leave-one-out  
296 cross-validation procedure (**Table 3**). Despite all variables were kept in the final  
297 analysis, it became obvious that the differences verified for the assayed ratios were not  
298 as significant as it would be necessary to obtain individualized groups. This can be  
299 clearly observed in **Figure 4**, in which several overlapping markers confirm the  
300 similarity among the assayed mixtures of artichoke, borututu and milk thistle.

301

## 302 **Conclusions**

303 Overall, the interaction among F and R was significant in all cases, indicating that the  
304 effects caused by each assayed formulation are related to the used proportion of each  
305 plant. Even so, syrups tended to be the formulation with highest antioxidant activity and  
306 the higher contents in total phenolics and flavonoids; this was specially verified when  
307 the mixture 1:1:2 was used, as it can be concluded from the estimated marginal mean

308 plots. On the other hand, pills were the worst formulation, independently of the used  
309 mixture. In what concerns artichoke:borututu:milk thistle ratios, the results did not  
310 reveal so observable differences. The higher influence of F in comparison with R was  
311 clearly highlighted by the LDA outputs. In addition, the effects of each factor were  
312 significantly different, since the correlations among discriminant functions and selected  
313 variables were different within each statistical test. The obtained outputs confirmed the  
314 significant differences among infusions, pills and syrups, showing also that the  
315 artichoke:borututu:milk thistle ratios used in the mixtures had much lower effects in the  
316 antioxidant activity assays and bioactive compounds contents.

317 With no exception, the mixtures for all formulations gave synergistic effects for  
318 antioxidant activity assays, and also in several assays regarding hepatocellular  
319 carcinoma toxicity, when compared to the activity of single plants. Moreover, none of  
320 the samples showed toxicity for liver primary cells.

321 The obtained results might be helpful to define the best formulation and mixing  
322 proportions to be used in the preparation of non-toxic products derived from artichoke,  
323 borututu and milk thistle.

324

### 325 **Competing interests**

326 The authors declare no competing financial interest.

327

### 328 **Acknowledgements**

329 The authors are grateful to Fundação para a Ciência e a Tecnologia (FCT, Portugal) for  
330 financial support to CIMO (strategic project PEst-OE/AGR/UI0690/2011). J.C.M.  
331 Barreira and R.C. Calhella thank FCT, POPH-QREN and FSE for their grants

332 (SFRH/BPD/68344/2010 and SFRH/BPD/72802/2010, respectively). L. Barros thanks  
333 “Compromisso para a Ciência 2008” for her contract.

334

### 335 **References**

- 336 1 V. Lattanzio, P.A. Kroon, V. Linsalata, A. Cardinali, *J. Funct. Foods*, 2009, 1,  
337 131-144.
- 338 2 Shaker E, Mahmoud, Mnaa S. *Food Chem Toxicol.*, 2010, 48, 803-806.
- 339 3 J.R.A. Silva, A.S. Ramos, M. Machado, D.F. Moura, Z. Neto, M.M. Canto-  
340 Cavaleiro, P. Figueiredo, V.E. Rosario, A.C.F. Amaral, D. Lopes, *Memórias do*  
341 *Instituto Oswaldo Cruz* 2011, 106, 142-158.
- 342 4 W. Presber, D.K. Herrman, B. Hegenscheid, *Angewandte Parasitol*, 1991, 32, 7-  
343 9.
- 344 5 F. Rainone, *Am. Fam. Phys.*, 2005, 72, 1285-1292.
- 345 6 I. Koubaa, M. Damak, A. McKillop, M. Simmonds, *Fitoterapia*, 1999, 70, 212-  
346 213.
- 347 7 O.F. Kunle, H.O. Egharevba, O.P. Ahmadu, *Int. J. Biodiv. Conserv*, 2012, 4,  
348 101-112.
- 349 8 R. Bauer, *Drug Inf. J.*, 1998, 32, 101-110.
- 350 9 L.V. Jacociunas, H.H.R. Andrade, M. Lehmann, B.R.R. Abreu, A.B.F. Ferraz, J.  
351 Silva, I. Grivicich, R.R. Dihl, *Food Chem. Toxicol.*, 2013, 55, 56-59.
- 352 10 J. Doehmer, G. Weiss, G.P. McGregor, K. Appel, *Toxicol. In Vitro*, 2011, 25,  
353 21-27.
- 354 11 B. Halliwell, *Nutr. Rev.*, 2012, 70:257-265.
- 355 12 J.W. Wu, L.C. Lin, T.W. Tsai, *J. Ethnopharmacol.*, 2009, 121, 185-193.



- 356 13 C. Pereira, R.C. Calhella, L. Barros, I.C.F.R. Ferreira, *Ind. Crops Prod.*, 2013,  
357 49, 61-65.
- 358 14 C. Pereira, R.C. Calhella, L. Barros, M.J.R.P. Queiroz, I.C.F.R. Ferreira, *Ind.*  
359 *Crops Prod.*, 2014, 52, 709-713.
- 360 15 A. Martins, L. Barros, A.M. Carvalho, C. Santos-Buelga, I.P. Fernandes, F.  
361 Barreiro, I.C.F.R. Ferreira, *Food & Function*, 2014. Doi: 10.1039/C3FO60721F
- 362 16 Pereira C, Barros L, Vilas-Boas M, Ferreira ICFR (2013b) *Int J Food Sci Nutr*  
363 64:230-234.
- 364 17 D.S. Stojković, J. Petrovic, F. Reis, L. Barros, J. Glamocilija, A. Ciric, I.C.F.R.  
365 Ferreira, M. Sokovic, *Food & Function*, 2014. Doi:10.1039/C4FO00113C
- 366 18 A. López, P. García, A. Garrido, *Food Chem.*, 2008, 106, 369-378.
- 367 19 J. Maroco, *Edições Sílabo*, Lisboa, Portugal, 2003.
- 368 20 J. Dai, R.J. Mumper, *Molecules*, 2010, 15, 7313-7352.
- 369 21 N. Razali, S. Mat-Junit, A.F. Abdul-Muthalib, S. Subramaniam, A. Abdul-Aziz,  
370 *Food Chem.*, 2012, 131, 441-448.
- 371 22 R. Guimarães, L. Barros, A.M. Carvalho, I.C.F.R. Ferreira, *Phyther. Res.*,  
372 2011, 25, 1209-1214.



**Table 1.** *In vitro* antioxidant properties ( $EC_{50}$ , mg/mL) and bioactive compounds content for the different formulations prepared from artichoke (A), borututu (B) and milk thistle (M). The results are presented as mean $\pm$ SD<sup>a</sup>.

		Total phenolics (mg GAE/g)	Total flavonoids (mg CE/g)	DPPH scavenging activity	Reducing power	$\beta$ -Carotene bleaching inhibition	TBARS formation inhibition
Formulation (F)	infusion	148 $\pm$ 19	34 $\pm$ 4	0.4 $\pm$ 0.1	0.2 $\pm$ 0.1	0.15 $\pm$ 0.03	0.06 $\pm$ 0.01
	pill	69 $\pm$ 11	5 $\pm$ 1	1.2 $\pm$ 0.4	0.4 $\pm$ 0.1	2 $\pm$ 1	0.3 $\pm$ 0.1
	syrup	469 $\pm$ 164	78 $\pm$ 32	0.3 $\pm$ 0.2	0.06 $\pm$ 0.02	0.10 $\pm$ 0.02	0.03 $\pm$ 0.01
	<i>p</i> -value (n=36)	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
A:B:M ratio (R)	1:1:1	232 $\pm$ 178	38 $\pm$ 33	0.6 $\pm$ 0.2	0.2 $\pm$ 0.1	0.3 $\pm$ 0.3	0.2 $\pm$ 0.2
	2:1:1	172 $\pm$ 112	31 $\pm$ 20	1.0 $\pm$ 0.5	0.3 $\pm$ 0.2	1 $\pm$ 1	0.1 $\pm$ 0.1
	1:2:1	198 $\pm$ 121	31 $\pm$ 20	0.5 $\pm$ 0.4	0.2 $\pm$ 0.1	1 $\pm$ 1	0.1 $\pm$ 0.1
	1:1:2	312 $\pm$ 301	55 $\pm$ 54	0.6 $\pm$ 0.4	0.3 $\pm$ 0.2	2 $\pm$ 2	0.1 $\pm$ 0.1
	<i>p</i> -value (n=27)	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
F $\times$ R	<i>p</i> -value (n=108)	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

$EC_{50}$ - extract concentration corresponding to 50% of antioxidant activity or 0.5 of absorbance for the Ferricyanide/Prussian blue assay (reducing power).


**Table 2.** Theoretical<sup>a</sup> versus experimental values of antioxidant EC<sub>50</sub> (mg/mL) and antiproliferative GI<sub>50</sub> (μg/mL) activities of different mixtures and formulations.

Bioactivity	Theoretical	Experimental	Effect	Theoretical	Experimental	Effect	Theoretical	Experimental	Effect	Theoretical	Experimental	Effect
	1:1:1			2:1:1			1:2:1			1:1:2		
Infusion												
DPPH scavenging activity	1.56	0.38±0.02	SN	1.72	0.42±0.04	SN	1.22	0.25±0.02	SN	1.80	0.48±0.03	SN
Reducing power	1.22	0.16±0.01	SN	1.38	0.30±0.02	SN	0.97	0.18±0.01	SN	1.36	0.32±0.02	SN
β-carotene bleaching inhibition	1.21	0.11±0.01	SN	1.34	0.16±0.01	SN	1.07	0.13±0.01	SN	1.26	0.18±0.01	SN
TBARS inhibition	0.17	0.06±0.01	SN	0.16	0.06±0.01	SN	0.13	0.04±0.01	SN	0.22	0.07±0.01	SN
HepG2 (hepatocellular carcinoma)	199.37	24±1	SN	162.55	49±8	SN	186.05	63±7	SN	249.53	67±2	SN
Pill												
DPPH scavenging activity	6.46	0.85±0.05	SN	7.43	1.85±0.03	SN	5.22	1.07±0.03	SN	6.94	1.12±0.04	SN
Reducing power	1.31	0.38±0.02	SN	1.56	0.49±0.02	SN	1.14	0.35±0.03	SN	1.27	0.43±0.02	SN
β-carotene bleaching inhibition	7.70	0.77±0.04	SN	5.84	2.35±0.05	SN	7.24	1.82±0.05	SN	10.27	4.19±0.05	SN
TBARS inhibition	0.86	0.43±0.02	SN	1.03	0.29±0.01	SN	0.74	0.17±0.01	SN	0.85	0.25±0.02	SN
HepG2 (hepatocellular carcinoma)	400	360±14	SN	400	>400	AD	400	340±2	SN	400	>400	AD
Syrup												
DPPH scavenging activity	74.89	0.43±0.02	SN	113.05	0.66±0.05	SN	57.07	0.18±0.02	SN	56.81	0.11±0.01	SN
Reducing power	24.51	0.05±0.01	SN	36.85	0.08±0.01	SN	18.83	0.08±0.01	SN	18.58	0.03±0.01	SN
β-carotene bleaching inhibition	5.91	0.10±0.01	SN	8.82	0.13±0.01	SN	4.61	0.12±0.01	SN	4.48	0.07±0.01	SN
TBARS inhibition	7.08	0.03±0.01	SN	10.68	0.04±0.01	SN	5.40	0.04±0.01	SN	5.38	0.02±0.01	SN
HepG2 (hepatocellular carcinoma)	360.16	317±12	SN	370.12	>400	AN	370.12	>400	AN	340.24	>400	AN


<sup>a</sup>The theoretical values were obtained considering summative contributions of the individual species. A- Additive effect: theoretical and experimental EC<sub>50</sub>/GI<sub>50</sub> values reveal differences below 5%. S- Synergistic effect: experimental EC<sub>50</sub>/GI<sub>50</sub> values are more than 5% lower than theoretical values. AN - antagonist effect: experimental EC<sub>50</sub> values are more than 5% higher than theoretical values.

**Table 3.** Contingency matrix obtained using LDA based on antioxidant activity and bioactive compounds content in different artichoke:borututu: milk thistle ratios.

	Predicted group membership				Total	Sensitivity (%)
	1:1:1	2:1:1	1:2:1	1:1:2		
1:1:1	19	7	1	0	27	70
2:1:1	9	9	0	9	27	33
1:2:1	6	0	21	0	27	78
1:1:2	0	0	6	21	27	78
Total	34	16	28	30	108	65
Specificity (%)	56	56	75	70	64	




**Figure 1.** Interactions between formulation (F) and artichoke:borututu:milk thistle ratio (R) effects on bioactive compounds content. Total phenolics (A), total flavonoids (B).




**Figure 2.** Interactions between formulation (F) and artichoke:borututu:milk thistle ratio (R) on the antioxidant activity. DPPH scavenging activity (A), reducing power assay (B),  $\beta$ -carotene bleaching inhibition (C), TBARS formation inhibition (D).





**Figure 3.** Discriminant scores scatter plot of the canonical functions defined for bioactive compounds content and antioxidant activity results according with formulation.



**Figure 4.** Discriminant scores scatter plot of the canonical functions defined for bioactive compounds content and antioxidant activity results according with artichoke:borututu:milk thistle ratio.